Literature DB >> 24633563

Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology.

Elyes Dahmane1, Julien Boccard, Chantal Csajka, Serge Rudaz, Laurent Décosterd, Eric Genin, Bénédicte Duretz, Maciej Bromirski, Khalil Zaman, Bernard Testa, Bertrand Rochat.   

Abstract

Liquid-chromatography (LC) high-resolution (HR) mass spectrometry (MS) analysis can record HR full scans, a technique of detection that shows comparable selectivity and sensitivity to ion transitions (SRM) performed with triple-quadrupole (TQ)-MS but that allows de facto determination of "all" ions including drug metabolites. This could be of potential utility in in vivo drug metabolism and pharmacovigilance studies in order to have a more comprehensive insight in drug biotransformation profile differences in patients. This simultaneous quantitative and qualitative (Quan/Qual) approach has been tested with 20 patients chronically treated with tamoxifen (TAM). The absolute quantification of TAM and three metabolites in plasma was realized using HR- and TQ-MS and compared. The same LC-HR-MS analysis allowed the identification and relative quantification of 37 additional TAM metabolites. A number of new metabolites were detected in patients' plasma including metabolites identified as didemethyl-trihydroxy-TAM-glucoside and didemethyl-tetrahydroxy-TAM-glucoside conjugates corresponding to TAM with six and seven biotransformation steps, respectively. Multivariate analysis allowed relevant patterns of metabolites and ratios to be associated with TAM administration and CYP2D6 genotype. Two hydroxylated metabolites, α-OH-TAM and 4'-OH-TAM, were newly identified as putative CYP2D6 substrates. The relative quantification was precise (<20 %), and the semiquantitative estimation suggests that metabolite levels are non-negligible. Metabolites could play an important role in drug toxicity, but their impact on drug-related side effects has been partially neglected due to the tremendous effort needed with previous MS technologies. Using present HR-MS, this situation should evolve with the straightforward determination of drug metabolites, enlarging the possibilities in studying inter- and intra-patients drug metabolism variability and related effects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24633563     DOI: 10.1007/s00216-014-7682-2

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  7 in total

1.  Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs.

Authors:  Mahmud Hasan; Mohamed Akmal Marzouk; Saugat Adhikari; Thomas D Wright; Benton P Miller; Margarite D Matossian; Steven Elliott; Maryl Wright; Madlin Alzoubi; Bridgette M Collins-Burow; Matthew E Burow; Ulrike Holzgrabe; Darius P Zlotos; Robert E Stratford; Paula A Witt-Enderby
Journal:  Mol Pharmacol       Date:  2019-06-20       Impact factor: 4.436

2.  Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction.

Authors:  Yijin Liu; Michael Jann; Chad Vandenberg; Chin B Eap; Shahab A Shamsi
Journal:  J Chromatogr A       Date:  2015-10-03       Impact factor: 4.759

3.  A semi-automated, isotope-dilution high-resolution mass spectrometry assay for therapeutic drug monitoring of antidepressants.

Authors:  Johanna M Lindner; Michael Vogeser; Katharina Sorg; Stefanie H Grimm
Journal:  Clin Mass Spectrom       Date:  2019-05-21

4.  Tamoxifen toxicity in cultured retinal pigment epithelial cells is mediated by concurrent regulated cell death mechanisms.

Authors:  Leo A Kim; Dhanesh Amarnani; Gopalan Gnanaguru; Wen Allen Tseng; Demetrios G Vavvas; Patricia A D'Amore
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-07-03       Impact factor: 4.799

5.  New UPLC-MS/MS assay for the determination of tamoxifen and its metabolites in human plasma, application to patients.

Authors:  Christine Bobin-Dubigeon; Mario Campone; Elsa Rossignol; Estelle Salaun; Marie-Bernadette Amiand; Jean-Marie Bard
Journal:  Future Sci OA       Date:  2019-03-22

6.  Metabolite Profiling in Anticancer Drug Development: A Systematic Review.

Authors:  Nadda Muhamad; Kesara Na-Bangchang
Journal:  Drug Des Devel Ther       Date:  2020-04-09       Impact factor: 4.162

7.  Ultra-Performance Liquid Chromatography-High-Resolution Mass Spectrometry and Direct Infusion-High-Resolution Mass Spectrometry for Combined Exploratory and Targeted Metabolic Profiling of Human Urine.

Authors:  Elena Chekmeneva; Gonçalo Dos Santos Correia; María Gómez-Romero; Jeremiah Stamler; Queenie Chan; Paul Elliott; Jeremy K Nicholson; Elaine Holmes
Journal:  J Proteome Res       Date:  2018-09-19       Impact factor: 4.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.